Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
Phase 3
Completed
- Conditions
- Chronic Hepatitis B
- First Posted Date
- 2002-11-14
- Last Posted Date
- 2017-02-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 820
- Registration Number
- NCT00048945
A Study to Assess Use of Zenapax (Daclizumab) and CellCept (Mycophenolate Mofetil) to Improve Kidney Function in Kidney Transplant Patients
Phase 3
Completed
- Conditions
- Kidney Transplantation
- Interventions
- First Posted Date
- 2002-10-25
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 539
- Registration Number
- NCT00048152
A Study to Evaluate the Efficacy and Safety of Zenapax in Combination With CellCept, Cyclosporine, and Corticosteroids in Patients Undergoing Cardiac Transplantation
Phase 4
Completed
- Conditions
- Heart Transplantation
- Interventions
- First Posted Date
- 2002-10-25
- Last Posted Date
- 2016-06-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 434
- Registration Number
- NCT00048165
MOBILE Study - A Study of Bonviva (Ibandronate) Regimens in Women With Post-Menopausal Osteoporosis
Phase 3
Completed
- Conditions
- Post Menopausal Osteoporosis
- Interventions
- First Posted Date
- 2002-10-25
- Last Posted Date
- 2018-03-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1609
- Registration Number
- NCT00048061
A Study of Intravenous (iv) Mircera in Hemodialysis Patients With Chronic Renal Anemia
Phase 2
Completed
- Conditions
- Anemia
- Interventions
- Drug: methoxy polyethylene glycol-epoetin beta [Mircera]
- First Posted Date
- 2002-10-25
- Last Posted Date
- 2016-12-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 91
- Registration Number
- NCT00048035
DIVA Study - A Study of Different Regimens of Intravenous Administration of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis
Phase 3
Completed
- Conditions
- Post Menopausal Osteoporosis
- Interventions
- First Posted Date
- 2002-10-25
- Last Posted Date
- 2016-02-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1395
- Registration Number
- NCT00048074
Evaluation of Various Doses of Ro 27-2771 (Test Drug) in Asthmatic Patients Not Treated With Inhaled Corticosteroids
Phase 2
Completed
- Conditions
- Asthma
- First Posted Date
- 2002-10-25
- Last Posted Date
- 2017-06-19
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT00048009
Inhaled Corticosteroid Replacement Study - Efficacy and Safety of Ro 27-2441 (Test Drug) in Moderate Persistent Asthma
Phase 2
Completed
- Conditions
- Asthma
- First Posted Date
- 2002-10-25
- Last Posted Date
- 2017-06-19
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT00048022
A Study of Mircera in Anemic Patients With Chronic Kidney Disease Not Yet on Dialysis.
Phase 2
Completed
- Conditions
- Anemia
- Interventions
- Drug: methoxy polyethylene glycol-epoetin beta [Mircera]
- First Posted Date
- 2002-10-25
- Last Posted Date
- 2018-01-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 65
- Registration Number
- NCT00048048
A Study of Xeloda (Capecitabine) in Patients With Advanced and/or Metastatic Colorectal Cancer
- First Posted Date
- 2002-10-25
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 52
- Registration Number
- NCT00048139
© Copyright 2025. All Rights Reserved by MedPath